Status:
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial
Lead Sponsor:
Services Institute of Medical Sciences, Pakistan
Conditions:
Moderate to Severe Chronic Plaque Psoriasis
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
The goal of this clinical trial is to learn if Infliximab Biosimilar Remsima works to treat moderate to severe plaque Psoriasis in adults. It will also learn about the safety of the drug. The main que...
Eligibility Criteria
Inclusion
- Adult Patients of moderate to severe plaque psoriasis Biologically naive patients
Exclusion
- Patients with active or latent TB, Hepatitis B or C, HIV. Immunocompromised patients due to drugs or disease. Patients on systemic anti-psoriastic medications in last three months. Patients with personal or strong family history of heart disease. Any other medical comorbidity (hepatic or renal) or contraindication to biologic/ biosimilars.
Key Trial Info
Start Date :
November 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 5 2024
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT06591273
Start Date
November 6 2023
End Date
November 5 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology, Services Institute of Medical Sciences/ Services Hospital
Lahore, Punjab Province, Pakistan, 54000